Wound Healing of Oklahoma, Inc.

Immunophotonics, Inc.

Chiron Ophthalmics, Inc.

Medtronic Xomed, Inc.

Premier Laser Systems, Inc.

Wound Healings of Oklahoma

Dean A. Mcgee Eye Inst.

Corneal Contouring Development L.l.c.

Dean A. Mcgee Eye Institute

Robert E Nordquist

Wei R Chen

Raoul Carubelli

Joseph Raker

Bing Li

Luciano Alleruzzo

Peter Jenkins

Kristopher Waynant

Tomas Hode

Cary J Reich

Michael Lerner

David Gibson

Robert W Adams

Lauren G Kilmer

Kok-Ming Tai

Scott M Hampton

James E Memmen

David R Gibson

Michael Nadalsky

James R Lisk, Jr

Philip Vincent Robledo

Ming-Kok Tai

Siu Kit Lam

Phillip Vincent Robledo

James Reid Lisk

Carey Reich

Therapeutic compositions comprising chitosan-derived compositions are useful agents when administered in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.

Chitosan-derived compositions

The present invention relates generally to therapeutic compositions comprising chitosan-derived compositions used in connection with methods for treating neoplasms, such as for instance, malignant lung, thyroid and kidney neoplasms, and other types of malignant neoplasms, and other medical disorders.

An ophthalmic implant having a body for positioning in a recess created in the sclera, feet for positioning in the anterior chamber, and a neck between the body and the feet for positioning in a scleral opening created between the scleral recess and the anterior chamber. The implant feet extend beyond the implant body and have a curvature approximating the curvature of the anterior chamber. The implant has drainage passageways for draining ocular fluid from the anterior chamber. The passageways are formed in outer surfaces or through the interior of the implant. Interior passageways are formed in surfaces of layers of the implant or by voids in inner layers of the implant. Related methods include creating undercuts that receive outer portions of the implant body and creating a scleral opening that is longer than the implant neck.

Article and method for ocular aqueous drainage

Preparations containing glycated chitosan in a physiologically compatible carrier are described. Viscoelastic preparations comprise 1.0-12.0 percent by weight of glycated chitosan in an aqueous solution while lower viscosity solutions possess 0.1-0.5 percent by weight glycated chitosan. The otherwise free amino groups of the chitosan polymer are preferably 30-90% glycated and possess an average molecular weight of between 100,000 and 2,000,000 Daltons, and, most preferably between 100,000 and 1,000,000 Daltons.

Solutions and films of glycated chitosan

An apparatus for the delivery of laser light in a therapeutic environment including: a console; an optical waveguide wherein a first end of the waveguide is configured to expose a biological tissue to energy transmitted through the waveguide; a plurality of laser diodes housed within the console such that the light emitted by each of the diodes will illuminate a second end of the optical wave guide; and a power supply for providing electrical power to each laser diode. Preferably each laser diode is configured to produce a unique wavelength of light. The power supply provides an independently controllable output for each laser such that the exposure, both in terms of intensity and duration, to each wavelength of light may be controlled independently of the exposure to each of the other wavelengths of light.

Apparatus and method for delivery of laser light

The present invention combines physical and immunologic therapies for the treatment of neoplasms by conditioning a targeted neoplasm with an immunoadjuvant (also called immuno-modulator or immunopotentiator) and then physically destroying the conditioned neoplasm. A number of physical therapies can be used to achieve the physical destruction of the conditioned tumor mass.

Combined physical and immunotherapy for cancer

A method for treating a neoplasm, such as a malignant tumor, in humans and other animals, is disclosed. A chromophore and an immunoadjuvant are introduced into the neoplasm. The neoplasm is then lased at an irradiance sufficient to induce neoplastic cellular destruction and to stimulate the self-immunological defense system against neoplastic cellular multiplication.

Laser/sensitizer assisted immunotherapy

A method and apparatus for lowering the intraocular pressure of an eye are provided. The apparatus is a filtering implant comprising a cellulosic membrane adapted to extend from the anterior chamber of the eye through an opening in the limbus corneae to a drainage area beneath a scleral flap. In its most preferred embodiment, the cellulosic membrane consists essentially of a homopolymer of glucose units connected in a 1,4'-.beta. linkage. The implant is of a planar, generally rectangular shape. The method involves preparing and implanting the device within the eye such that it extends from the anterior chamber of the eye through an opening in the limbus corneae to a drainage area beneath a scleral flap.

Method and apparatus for lowering the intraocular pressure of an eye

A method for the delivery of laser light for therapeutic purposes, and, more specifically, for the treatment of buried tumors wherein multiple lasers are used to treat a deeply buried tumorous mass. In more particular, multiple lasers in a spatial array are used to simultaneous irradiate a tumor from a multiplicity of different directions. Tumors treated in this way are heated more homogeneously than those treated via conventional single-laser treatments. Additionally, a multiple source laser treatment scheme puts the enclosing normal tissue at lesser risk than it would be exposed to if the treatment were conducted using via a single laser source.

Laser light delivery method

A vision collimator for self-monitoring peripheral vision loss or central visual field limitation. The collimator includes a hand-held collimator housing having a viewing aperture for placement adjacent to the subject's eye. A lens projects an image to the eye, which image is formed by the terminal ends of the blades of an iris diaphragm. The angular size of the image is adjustable by opening or closing the iris diaphragm to obtain a measurement indicative of the peripheral vision loss or the central visual field limitation. A diffuser is positioned behind the iris diaphragm to provide an even back-illumination, and indicia markings indicate the measurement. The device is particularly suitable for home use by persons with glaucoma or macular degeneration.

Vision collimator

A field of view collimator for self-monitoring peripheral vision loss. The field of view collimator includes a hand-held housing having a viewing aperture for placement adjacent to the subject's eye. A lens projects an image to the eye. The image, in the form of a circular edge, is formed by an iris diaphragm positioned behind the lens. The angular size of the image is adjustable by opening or closing the iris diaphragm. A diffuser is positioned behind the iris diaphragm to provide an even back-illumination. Indicia markings indicate the measured field of view. The device is particularly suitable for home use by persons with glaucoma.

Field of vision collimator

Chitosan-derived biomaterials, and, more specifically, chitosan modified by the addition of a monosaccharide or oligosaccharide side chain to its free amino groups. The modified chitosan ('glycated chitosan') is preferably stabilized by reduction. In one particularly preferred embodiment, a galactose derivative of chitosan ('galacto-chitosan') is provided. The chitosan-derived biomaterials are useful in a myriad of biomedical applications, including as an immunoadjuvant in laser/sensitizer assisted immunotherapy.

Chitosan-derived biomaterials

A method and apparatus for lowering the intraocular pressure of an eye are provided. The apparatus of the invention is a filtering implant comprising a cellulosic membrane adapted to extend from the anterior chamber of the eye through an opening in the limbus corneae to a drainage area beneath a scleral flap. In its most preferred embodiment, the cellulosic membrane consists essentially of a homopolymer of glucose units connected in a 1,4'-.beta. linkage. The implant is of a planar, generally rectangular shape. The method of the invention involves preparing and implanting the device within the eye such that it extends from the anterior chamber of the eye through an opening in the limbus corneae to a drainage area beneath a scleral flap.

Growing community of inventors

Oklahoma City, OK, United States of America

Robert E Nordquist